Market Analysis and Insights: Global In Situ Hybridization Market
In situ hybridization (ISH) is a type of hybridization that uses a labeled complementary DNA, RNA or modified nucleic acids strand to localize a specific DNA or RNA sequence in a portion or section of tissue (in situ), or, if the tissue is small enough, in the entire tissue, in cells, and in circulating tumor cells (CTCs). This is distinct from immunohistochemistry, which usually localizes proteins in tissue sections.
The global In Situ Hybridization market size is projected to reach US$ 705 million by 2030, from US$ 545.2 million in 2022, at a CAGR of 3.3% during 2023-2030.
North America is expected to account for the largest share of the market in 2018. This can be attributed to growing clinical and research in cancer by biotechnology and pharmaceutical companies, government initiatives, increasing prevalence and diagnosis of cancer in the U.S. and Canada, and increasing adoption of companion diagnostics. Increased adoption of companion diagnostics is attributed to the development and launch of newer therapeutic agents. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. This can be attributed to the growing presence of international players in China and India, increasing cancer prevalence and diagnosis, and increased healthcare expenditure across the Asia-Pacific region are drivers for the in situ hybridization market in this region.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global In Situ Hybridization market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global In Situ Hybridization market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global In Situ Hybridization market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global In Situ Hybridization market.
Global In Situ Hybridization Scope and Market Size
In Situ Hybridization market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global In Situ Hybridization market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2030.
Segment by Type
Fluorescence In Situ Hybridization (FISH)
Chromogenic In Situ Hybridization
Segment by Application
Cancer Diagnosis
Immunology
Neuroscience
Cytology
Infectious Diseases
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Abbott Laboratories
Roche
Thermo Fisher Scientific
Merck
Agilent Technologies
Perkin Elmer
Danaher
Exiqon
Biogenex Laboratories
Advanced Cell Diagnostics
Bio Sb
